Adeza Biomedical Corporation Announces Initial Public Offering of Common Stock.

SUNNYVALE, Calif. -- Adeza Biomedical Corporation (NASDAQ:ADZA) today announced the pricing of its initial public offering of 3,750,000 shares of its common stock at a price of $16.00 per share. All of the shares are being offered by Adeza. Adeza has granted to the underwriters a 30-day option to purchase up to an additional 562,500 shares at the initial public offering price to cover over-allotments, if any.

UBS Securities LLC is acting as the sole book-running manager of the offering. SG Cowen & Co., Thomas Weisel Partners LLC and William Blair & Company are acting as co-managers of the offering. Copies of the prospectus relating to the offering can be obtained from UBS Securities LLC, Attention: Prospectus Dept., 299 Park Avenue, New York, NY 10171.

The offering is made only by means of a prospectus. This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there by any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare, using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, the Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. This product is approved by the U.S. Food and Drug Administration (FDA) for broad use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity(R) Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility.